Report on a preclinical mitochondria-targeted small-molecule obesity therapy that reportedly beat a leading incretin comparator in a diet-induced mouse model.
Key Takeaways
- MTRX31 reduced body weight by 38.4 percent versus vehicle in mice
- Tirzepatide reduced body weight by 29.7 percent in the same study
- Combining MTRX31 with tirzepatide achieved 50.64 percent bodyweight loss in mice